Biblio

80 resultats trouvés
Filtres: Auteur is Andre, Thierry  [Clear All Filters]
P
Huynh T-K, Meeus P, Cassier P, Bouche O, Lardiere-Deguelte S, Adenis A, Andre T, Mancini J, Collard O, Montemurro M et al..  2014.  Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. BMC CANCER. 14:156.
Tougeron D, Sueur B, Zaanan A, de la Fouchardiere C, Sefrioui D, Lecomte T, Aparicio T, Guetz GDes, Artru P, Hautefeuille V et al..  2020.  Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. INTERNATIONAL JOURNAL OF CANCER. 147:285-296.
Vernerey D, Hammel P, Paget-Bailly S, Huguet F, Van Laethem JLuc, Goldstein D, Glimelius B, Artru P, Moore M, Andre T et al..  2014.  Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. JOURNAL OF CLINICAL ONCOLOGY. 32
Vernerey D, Hammel P, Paget-Bailly S, Huguet F, Van Laethem JLuc, Goldstein D, Glimelius B, Artru P, Moore MJ, Andre T et al..  2015.  Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial. JOURNAL OF CLINICAL ONCOLOGY. 33
Pages F, Andre T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L et al..  2020.  Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).. JOURNAL OF CLINICAL ONCOLOGY. 38
Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem J-L, Glimelius B, Artru P, Moore MJ, Andre T et al..  2016.  Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). BRITISH JOURNAL OF CANCER. 115:281-289.
Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M et al..  2021.  Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. CLINICAL CANCER RESEARCH. 27:5638-5646.
Delattre JFrancois, Cohen R, Henriques J, Falcoz A, Emile J-F, Fratte S, Chibaudel B, Dauba J, Dupuis OJean Marie, Becouarn Y et al..  2019.  Prognostic value of tumor deposits for disease free survival in patients with stage Ill colon cancer: A post hoc analysis of IDEA France phase Ill trial (PRODIGE-GERCOR).. JOURNAL OF CLINICAL ONCOLOGY. 37
Delattre J-F, Cohen R, Henriques J, Falcoz A, Emile J-F, Fratte S, Chibaudel B, Dauba J, Dupuis O, Becouarn Y et al..  2020.  Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). JOURNAL OF CLINICAL ONCOLOGY. 38:1702+.
Crombe A, Kind M, Ray-Coquard I, Isambert N, Chevreau C, Andre T, Lebbe C, Le Cesne A, Bompas E, Piperno-Neumann S et al..  2020.  Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. AMERICAN JOURNAL OF ROENTGENOLOGY. 215:1539-1548.
Shi Q, Sobrero AF, Shields AFrank, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA et al..  2017.  Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemother. JOURNAL OF CLINICAL ONCOLOGY. 35
Shi Q, Sobrero AF, Shields AFrank, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA et al..  2017.  Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemother. JOURNAL OF CLINICAL ONCOLOGY. 35
Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T, Gornet J-M, Aparicio T, Nguyen S, Azzedine A et al..  2014.  Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Federation Francophone de Cancerologie Digestive, Fed. JOURNAL OF CLINICAL ONCOLOGY. 32:3520+.
R
Lucidarme O, Wagner M, Gillard P, Kim S, Bachet J-B, Rousseau B, Mazard T, Louvet C, Chibaudel B, Cohen R et al..  2019.  RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. CANCER IMAGING. 19:85.
Cohen R, Bennouna J, Henriques J, Tournigand C, de la Fouchardiere C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol M-L et al..  2020.  RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II. JOURNAL OF CLINICAL ONCOLOGY. 38
Cohen R, Bennouna J, Meurisse A, Tournigand C, de la Fouchardiere C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol M-L et al..  2020.  RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 8:e001499.
Cohen R, Bennouna J, Henriques J, Tournigand C, de la Fouchardiere C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol M-L et al..  2020.  RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II. JOURNAL OF CLINICAL ONCOLOGY. 38
Gerard J-P, Andre T, Bibeau F, Conroy T, Legoux J-L, Portier G, Bosset J-F, Cadiot G, Bouche O, Bedenne L et al..  2017.  Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). DIGESTIVE AND LIVER DISEASE. 49:359-367.
Taieb J, Andre T, Auclin E.  2019.  Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. CANCER TREATMENT REVIEWS. 75:1-11.
S
Bay J-O, Andre T, Caux C, Evrard S, Goncalves A, L'Allemain G, Magne N, Orbach D, Penel N, Rodrigues M et al..  2019.  Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer. BULLETIN DU CANCER. 106:12-23.
Chibaudel B, Tournigand C, Bonnetain F, de Larauze MHug, De Gramont A, Laurent-Pulg P, Louvet C, Andre T, de Gramont A, GERCOR.  2014.  Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer : A gercor randomized open-label phase III study.. JOURNAL OF CLINICAL ONCOLOGY. 32
Chibaudel B, Bonnetain F, Tournigand C, de Larauze MHug, De Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M et al..  2015.  STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC CANCER. 15:496.
T
Andre T, de Gramont A, Mineur L, Desrame J, Faroux R, Bennouna J, Dauba J, Louvet C, Pernot S, Dupuis OJean Marie et al..  2016.  The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients' characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.. JOURNAL OF CLINICAL ONCOLOGY. 34
Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, Andre T, de Gramont A.  2015.  Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 7:153-169.
Andre T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, de Larauze MHug, Paget-Bailly S, Chibaudel B et al..  2018.  Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. JOURNAL OF CLINICAL ONCOLOGY. 36:1469+.

Pages